Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Kiora Pharmaceuticals

07/08/2026 12:34

Kiora Pharmaceuticals, Inc. KPRX.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -54 cents.  The lone analyst forecast for the quarter was for a loss of 62 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Kiora Pharmaceuticals, Inc.'s reported EPS for the quarter was a loss of 34 cents​.
The company reported a quarterly loss of $2.08 million.
Kiora Pharmaceuticals, Inc. shares had fallen by 2.7% this quarter and gained 29.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Kiora Pharmaceuticals, Inc. is $12.00, about 78.7% above its last closing price of $2.56
This summary was machine generated from LSEG data August 7 at 11:34 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.62
-0.34
Beat
Mar. 31 2026 
-0.71
-0.58
Beat
Dec. 31 2025 
-0.67
-1.59
Missed
Sep. 30 2025 
-0.73
0.01
Beat